Palbociclib

Palbociclib

产品活性：Palbociclib (PD 0332991) is a selective CDK4 and CDK6 inhibitor with IC₅₀s of 11 and 16 nM, respectively. Palbociclib is a drug for the treatment of ER-positive and HER2-negative breast cancer.

研究领域：Cell Cycle/DNA Damage

作用靶点：CDK

In Vitro: The IC₅₀ of Palbociclib (PD 0332991) for reduction of retinoblastoma (Rb) phosphorylation at Ser⁷⁸⁰ in MDA-MB-435 breast carcinoma cells is 66 nM. Palbociclib is equally effective at reducing Rb phosphorylation at Ser⁷⁹⁵ in this tumor with an IC₅₀ of 63 nM, and similar effects on both Ser⁷⁸⁰ and Ser⁷⁹⁵ phosphorylation are obtained in the Colo-205 colon carcinoma^[1]. The MP-MRT-AN (AN), KP-MRT-RY (RY), G401, and KP-MRT-NS (NS) cell lines are effectively inhibited by Palbociclib (PD) in a concentration-dependent manner in a WST-8 assay. The IC₅₀s are 0.01 µM, 0.01 µM, 0.06 µM, and 0.6 µM, respectively. In contrast, the KP-MRT-YM (YM) cell line is resistant to Palbociclib (IC₅₀>10 µM). The flow cytometry results show that Palbociclib at concentrations between 0 to 1.0 µM induces G1 arrest in the AN, RY, G401 and NS cell lines in a concentration-dependent manner, but has no effect on YM cells. The BrdU incorporation results are consistent with the WST-8 and flow cytometry results: PD reduces BrdU incorporation (indicating G1 arrest) in the AN, RY, G401 and NS cell lines, but not in the YM cell line. Palbociclib, even at a concentration of 0.05 µM, significantly reduces BrdU incorporation in the AN, RY, and G401 cell lines (p<0.05)^[2].

In Vivo: Palbociclib (PD 0332991) exhibits significant antitumor efficacy against multiple human tumor xenograft models. In mice bearing Colo-205 colon carcinoma xenografts (p16 deleted), daily p.o. dosing for 14 days with Palbociclib (150 or 75 mg/kg) produces rapid tumor regressions and a corresponding tumor growth delay of ~50 days with >1 log of tumor cell kill at the highest dose tested. At 37.5 mg/kg, the tumor slowly regressed during treatment. Even at doses as low as 12.5 mg/kg, a 13-day growth delay is obtained indicating a 90% inhibition of tumor growth rate. Likewise, robust antitumor activity is seen in the MDA-MB-435 breast carcinoma (p16 deleted) where complete tumor stasis is apparent at 150 mg/kg and some cell kill is evident at the highest dose^[1].

相关产品：Peptidomimetic Library  |  Bioactive Compound Library Plus  |  Abemaciclib methanesulfonate  |  Palbociclib hydrochloride  |  Ribociclib  |  Dinaciclib  |  THZ531  |  THZ1  |  Seliciclib  |  NVP-2  |  Ro-3306  |  Flavopiridol  |  CYC065  |  Atuveciclib Racemate  |  AZD4573  |  SNS-032  |  SB1317  |  GSK 3 Inhibitor IX  |  AZD-5438  |  Kenpaullone  |  CDK9-IN-2  |  BS-181  |  CT7001 hydrochloride  |  THZ2  |  CCT-251921  |  (+)-BAY-1251152  |  Milciclib  |  PHA-767491 hydrochloride

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。